Taconic Hosts First Annual Global R&D Meeting
Taconic announced that it recently held its first annual Global R&D Symposium, bringing together renowned industry experts, scientific leaders from academia and scientists from the various functional areas within Taconic responsible for driving new product, technology and service innovations. The international meeting, which included participants from the United States and Europe and was held September 3 and 4, was part of Taconic’s long-term strategic planning initiative, focused on achieving the goal of developing new and more predictive mouse and rat models for drug discovery and pre-clinical development.
“Across the globe, Taconic possesses an unrivaled depth of expertise in the science and technology that is the backbone of model creation,” said Todd Little, President of Taconic. “By better integrating our research and development capabilities on an international level, Taconic will be well positioned to strengthen our contribution to optimize drug discovery by developing new, innovative model creation technologies and animal models for the research community in industry and academia.”
The meeting brought together prominent scientists and industry leaders from Taconic’s international Research and Development sites and the research community representing diverse areas of expertise, including molecular biology, cell biology, embryology, virology, immunology and veterinary sciences.
Key participants and speakers included:
— Keynote speaker Dr. Klaus Rajewsky, CBR Institute for Biomedical Research, Harvard Medical School and a pioneer in the field of biomedical sciences. Rajewksy was previously a member of the Board of Directors of the Institute for Genetics at the University of Cologne and Programme Coordinator for the EMBL Mouse Biology Programme. He has served on numerous research and scientific advisory boards internationally and is a frequent lecturer in the fields of genetics and immunology. Professor Rajewsky is one of the most prominent immunologists and mouse geneticists worldwide.
— Dr. Alexandra Glucksmann, Senior Vice President of Research and Business Operations, Tempo Pharmaceuticals and member of the Taconic Board of Directors. Glucksmann serves on the Genetics Advisory Council of the Harvard-Partners Center for Genetics and Genomics and is a widely published author on varied genetics topics, including RNA.
— Dr. Peter J. W. Stadler, Managing Director, TaconicArtemis. Stadler previously served as head of Pharma-Biotechnology at Bayer AG before co-founding ARTEMIS Pharmaceuticals in 1998, for which he served as Managing Director. His insights on genetic engineering have been widely published, and he was awarded for his contributions to the field of biotechnology in Germany.
— Dr. Jost Seibler, Head of Technology Development and RNAi Research at TaconicArtemis. Seibler has been instrumental in developing proprietary knockdown systems at TaconicArtemis, where he leads a group focused on the development of novel RNAi-based technologies for inducible and reversible knockdown of genes, for targeted transgenesis and mouse disease models. While at the National Research Center for Biotechnology in Braunschweig, Germany, he developed recombinase-based technologies for genetic engineering of the mouse genome based on embryonic stem cells.
— Dr. George Scangos, Ph.D., CEO of Exelixis, Inc. Prior to joining Exelixis as President/CEO, Scangos served as President of Biotechnology at Bayer Corporation, responsible for research, business and process development, manufacturing, and quality assurance. He is Chairman of the Board of Directors of Anadys Pharmaceuticals, Inc. and Entelos, Inc., an adjunct professor of biology at Johns Hopkins University and a member of the Board of BIO.
Taconic Farms, Inc. was founded in 1952 as a family-owned business in New York’s Hudson River Valley. Since then, the company has become one of the largest laboratory rodent providers in the world with a reputation for consistently producing high quality, well-defined rats and mice. Taconic’s expertise in the custom design and generation of genetically modified mice, mouse and rat breeding, barrier systems, genetics and animal health supports researchers focused on drug development using in vivo models. Taconic has six breeding facilities and three service laboratories in the USA and Europe, a staff of over 1,000, and a commitment to technological innovation. Taconic’s subsidiary TaconicArtemis, located in Cologne, Germany, possesses the worldwide leading portfolio of scientific methods in the field of mouse molecular genetics. Additional information about Taconic is available through its corporate website, www.taconic.com.